Cleaved-MMP1 (F100) Antibody

What is Cleaved-MMP1 (F100) Antibody and what specific epitope does it recognize?

Cleaved-MMP1 (F100) Antibody specifically detects endogenous levels of the fragment of activated MMP-1 (Matrix Metalloproteinase-1) protein resulting from cleavage adjacent to phenylalanine at position 100 (F100). This antibody recognizes the internal region of human MMP-1 at the amino acid range 81-130, specifically targeting the cleaved form that results when the enzyme is activated .

The antibody is available in both polyclonal and monoclonal formats. The polyclonal version is typically derived from rabbit antiserum by affinity-chromatography using epitope-specific immunogen, while the monoclonal version is derived from mouse . Both formats are designed to detect the specific cleaved fragment of activated MMP-1 that occurs during its proteolytic activation.

What is the biological significance of the F100 cleavage site in MMP1 activation?

The F100-V101 bond represents a critical cleavage site in MMP1 activation. Upon activation by proteases such as trypsin, MMP1 is cleaved at this specific site, resulting in removal of the pro-domain and exposure of the catalytic site . This proteolytic processing is essential for converting the inactive zymogen to its catalytically active form.

The cleaved MMP1 (from V101 to N469) represents the active enzyme capable of degrading extracellular matrix components, particularly fibrillar collagens. This post-activation cleavage is crucial for MMP1's biological functions, including extracellular matrix remodeling, wound healing, and its pathological roles in cancer, arthritis, and fibrosis . The antibody's specificity for this cleaved form makes it valuable for distinguishing between inactive pro-MMP1 and its activated counterpart.

How does MMP1 compare structurally and functionally to other MMPs in the family?

MMP1 belongs to the matrix metalloproteinase family but has distinct structural and functional characteristics:

Comparative analysis with MMP3 and other MMPs reveals both overlapping and distinct functions, with MMP1 being particularly specialized for fibrillar collagen degradation .

What are the validated applications for Cleaved-MMP1 (F100) Antibody in research?

Cleaved-MMP1 (F100) Antibody has been validated for several research applications:

• Western Blot (WB): The antibody can be used to detect cleaved MMP1 in protein lysates with recommended dilutions ranging from 1:500 to 1:2000 .

• Enzyme-Linked Immunosorbent Assay (ELISA): For detecting cleaved MMP1 in solution samples with recommended dilutions of approximately 1:20000 .

• Cell-Based Colorimetric ELISA: For measuring Cleaved-MMP-1 22k (F100) protein concentration in cells, allowing for quantitative analysis of MMP1 activation under different experimental conditions .

• Immunohistochemistry (IHC): While not explicitly mentioned for the F100-specific antibody in the provided references, related MMP antibodies have applications in IHC with dilutions ranging from 1:20 to 1:200 .

The antibody has been tested and validated in human samples, with some versions also showing reactivity to rat and mouse samples . For optimal results, researchers should follow the specific protocols provided by the manufacturer for each application.

How should I design experiments to study MMP1 activation and cleavage dynamics?

When designing experiments to study MMP1 activation and cleavage dynamics, consider the following methodological approach:

• Selection of appropriate model systems:

  • Cell lines known to express MMP1 (e.g., A549 cells as referenced in Western Blot analyses)

  • In vitro studies using purified MMP1 proteins (both pro-form and activated forms)

  • Animal models where MMP1 plays significant roles (noting species differences - mouse studies should consider Mmp1a, the functional mouse homologue of human MMP1)

• Activation protocols:

  • In vitro activation using trypsin to cleave at the F100-V101 bond

  • APMA (4-aminophenylmercuric acetate) activation for controlled conditions

  • Physiological activators such as plasmin or other proteases

• Dynamic analysis techniques:

  • Single-molecule Förster Resonance Energy Transfer (FRET) to study interdomain dynamics, as demonstrated in research where MMP1 was labeled with Alexa555 and Alexa647 at positions 142 and 366 to monitor conformational changes

  • All-atom molecular dynamics simulations to analyze structural changes during activation and substrate binding

  • Time-course experiments to track the progression of MMP1 activation and substrate cleavage

• Quantification methods:

  • Densitometric analysis of Western blots to quantify cleaved versus uncleaved MMP1

  • Activity assays using fluorogenic substrates to measure enzymatic activity

  • Cell-based colorimetric ELISA for quantifying cleaved MMP1 levels in cellular contexts

• Controls:

  • Include catalytically inactive MMP1 mutants (e.g., E219Q mutation) for comparison

  • Use inhibitors like tetracycline to modulate MMP1 activity

  • Compare with other MMPs (e.g., MMP9) that have different substrate specificities

What are the technical considerations for optimal Western blot detection using this antibody?

For optimal Western blot detection using Cleaved-MMP1 (F100) Antibody, consider these technical parameters:

• Sample preparation:

  • Cell lysates: A549 cells have been successfully used for detecting cleaved MMP1

  • Protein denaturation: Use standard SDS-PAGE conditions with reducing agents

  • Loading controls: Include appropriate housekeeping proteins for normalization

• Antibody dilution and incubation:

  • Recommended dilution range: 1:500-1:2000 for Western blot applications

  • Primary antibody incubation: Follow manufacturer's recommendations (typically overnight at 4°C)

  • Secondary antibody: Use appropriate anti-rabbit IgG HRP-conjugated antibody for polyclonal versions or anti-mouse IgG for monoclonal versions

• Detection parameters:

  • Expected molecular weight: Approximately 22kDa for the cleaved MMP1 fragment (F100)

  • Detection method: Standard ECL (enhanced chemiluminescence) is suitable

  • Exposure time: Start with short exposures and increase as needed to avoid overexposure

• Buffer compositions:

  • Blocking buffer: Typically 5% non-fat dry milk or BSA in TBST

  • Washing buffer: Tris-buffered saline with 0.1% Tween-20 (TBST)

  • Formulation of antibody: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide

• Storage and handling:

  • Storage temperature: -20°C for long-term or 2-8°C for up to 2 weeks

  • Avoid repeated freeze-thaw cycles

  • Aliquot antibody upon first thaw to minimize degradation

• Troubleshooting considerations:

  • Non-specific bands: May require optimization of blocking conditions or antibody dilution

  • Weak signal: Consider longer exposure times, increased antibody concentration, or enhanced detection systems

  • High background: Increase washing steps or adjust blocking conditions

How can I use this antibody to investigate allosteric regulation of MMP1 activity?

To investigate allosteric regulation of MMP1 activity using Cleaved-MMP1 (F100) Antibody:

• Conformational state analysis:

  • Combine Cleaved-MMP1 (F100) Antibody detection with conformational studies using FRET-labeled MMP1 to correlate cleavage state with specific conformations

  • Research has shown that "functionally relevant MMP1 conformations have the catalytic and hemopexin domains distant" and these conformations are "present in active MMP1 but are significantly absent in inactive MMP1"

• Domain interaction studies:

  • Use the antibody in combination with domain-specific antibodies to map interactions between the catalytic domain and hemopexin domain during activation

  • Research indicates that "MMP1 opens its catalytic domain more compared with inactive MMP1"

• Modulator screening:

  • Use the antibody to detect cleaved MMP1 levels after treatment with potential allosteric modulators

  • Example: Tetracycline has been shown to inhibit specific conformations of MMP1

  • Compare with effects of other MMPs (e.g., "MMP9 enhances the low FRET conformations" of MMP1)

• Correlation with enzymatic activity:

  • Develop assays that simultaneously measure cleaved MMP1 detection by the antibody and enzymatic activity

  • This allows for establishing relationships between specific conformational states and catalytic efficiency

• Computational modeling integration:

  • Use molecular dynamics simulations to predict allosteric sites that could affect the F100 cleavage region

  • Validate these predictions using the antibody to detect changes in MMP1 cleavage patterns

  • Research has employed "Gromacs 2019.6 with the Gromos96 43a1 force field to perform the MD simulations" for studying MMP1 dynamics

What is the relationship between MMP1 cleavage, substrate specificity, and collagen degradation?

The relationship between MMP1 cleavage, substrate specificity, and collagen degradation is complex and multi-faceted:

How can I use bioinformatic approaches to predict and validate MMP1 cleavage sites in novel substrates?

Bioinformatic approaches for predicting and validating MMP1 cleavage sites can be integrated with experimental validation using Cleaved-MMP1 (F100) Antibody:

• Prediction algorithms and tools:

  • CleavPredict methodology developed based on phage display experiments can be used "for predicting and ranking the cleavage positions in the protein substrates" for MMPs including MMP1

  • This approach employs "positional weight matrices (PWM) for defining the scoring function that discriminates the cleavable peptide bonds from the non-cleavable ones"

  • The accuracy of PWM predictions has been validated with "high throughput multiplexed peptide-centric profiling technology involving the cleavage of 18,583 peptides by 18 proteinases" with correlation levels of "92%–99.7%"

• Structural considerations in prediction:

  • CleavPredict provides "information about the structural features of the potential cleavage sites that may affect MMP proteolysis"

  • This includes "annotation of the secondary structure, the disordered regions, the transmembrane domains, and the solvent accessibility parameter"

  • Additional filters can "discriminate between the cleavable and non-cleavable peptide bonds using the predicted structural elements"

• Experimental validation workflow:

  • Use bioinformatic tools to predict potential cleavage sites in proteins of interest

  • Design recombinant proteins or synthetic peptides containing these sites

  • Incubate with activated MMP1 and analyze cleavage products

  • Use Cleaved-MMP1 (F100) Antibody to detect and validate the specific cleavage events

  • Confirm cleavage site identity through mass spectrometry analysis

• Integrative analysis considerations:

  • Consider that "putative cleaved bonds represent 3.3–5.3% relative to all available peptide bonds in the soluble and membrane human proteins"

  • Apply structural filters: "acceptance of the putative cleavages that are located in the predicted structural loops, the unstructured sequence regions and also the cleavages located between two distinct secondary structures elements"

  • Compare experimental results with predictions to refine models of MMP1 specificity

What could cause false positive or negative results when using Cleaved-MMP1 (F100) Antibody?

Several factors can lead to false positive or negative results when using Cleaved-MMP1 (F100) Antibody:

Potential causes of false positives:

• Cross-reactivity issues:

  • The antibody may cross-react with other cleaved MMPs, particularly those with similar sequences in the F100 region

  • Verify specificity by comparing results with known positive and negative controls

  • Consider pre-absorption with recombinant proteins to confirm specificity

• Sample preparation artifacts:

  • Inadvertent activation of MMP1 during sample preparation could generate cleaved forms

  • Include protease inhibitors during sample preparation

  • Compare fresh samples with those subjected to various handling conditions

• Non-specific binding:

  • Insufficient blocking or washing can lead to non-specific antibody binding

  • Optimize blocking conditions (concentration, time, temperature)

  • Increase washing steps and duration

Potential causes of false negatives:

• Epitope masking:

  • The F100 cleavage site may be masked by protein-protein interactions

  • Use denaturing conditions to expose the epitope

  • Try alternative sample preparation methods

• Low abundance issues:

  • Cleaved MMP1 may be present below detection limits

  • Consider enrichment techniques or more sensitive detection methods

  • Optimize primary antibody incubation (time, temperature, concentration)

• Degradation concerns:

  • Cleaved MMP1 fragments may be rapidly degraded in certain samples

  • Add protease inhibitors immediately after sample collection

  • Process samples quickly and maintain cold chain

• Antibody storage/handling issues:

  • Improper storage leading to antibody degradation

  • Store according to manufacturer recommendations (typically -20°C)

  • Avoid repeated freeze-thaw cycles

  • Consider aliquoting the antibody upon first thaw

How can I differentiate between research findings related to inactive pro-MMP1 and cleaved active MMP1?

Differentiating between inactive pro-MMP1 and cleaved active MMP1 requires careful experimental design and interpretation:

• Molecular weight analysis:

  • Pro-MMP1 has a higher molecular weight (approximately 52-57 kDa) than the cleaved active form

  • The cleaved MMP1 fragment detected by the F100 antibody has a molecular weight of approximately 22 kDa

  • Use appropriate molecular weight markers in Western blot analysis

• Antibody selection strategy:

  • Use antibodies targeting different epitopes in parallel:

    • Cleaved-MMP1 (F100) Antibody specifically detects the activated form

    • Pro-domain-specific antibodies detect only the inactive form

    • C-terminal/hemopexin domain antibodies detect both forms

  • Compare signal patterns to distinguish the different forms

• Activity correlation:

  • Combine immunodetection with activity assays:

    • Collagenase activity assays using fluorogenic substrates

    • Zymography techniques to visualize active versus inactive forms

  • Correlate the presence of the cleaved form with enzymatic activity

• Activation-inhibition studies:

  • Treatment with activators (trypsin, APMA) should increase signal with Cleaved-MMP1 (F100) Antibody

  • Treatment with MMP inhibitors (e.g., tetracycline) should affect active MMP1 function but not necessarily detection of already cleaved forms

  • Use catalytically inactive mutants (E219Q) as controls that can be cleaved but remain enzymatically inactive

• Conformational analysis:

  • Combine with FRET analysis to correlate cleavage state with conformational changes

  • Research indicates specific conformations "are present in active MMP1 but are significantly absent in inactive MMP1"

  • Consider how "MMP1 opens its catalytic domain more compared with inactive MMP1"

How should I interpret contradictory results between cleaved MMP1 detection and functional activity assays?

When facing contradictory results between cleaved MMP1 detection and functional activity assays, consider these interpretive approaches:

How does Cleaved-MMP1 (F100) Antibody compare to antibodies targeting other MMP family members?

Comparing Cleaved-MMP1 (F100) Antibody with antibodies targeting other MMP family members reveals important similarities and differences:

• Epitope specificity comparison:

  • Cleaved-MMP1 (F100) Antibody: Targets the region around amino acids 81-130, specifically detecting the fragment resulting from cleavage adjacent to F100

  • Cleaved-MMP3 (F100) Antibody: Similarly targets a fragment of activated MMP-3 resulting from cleavage adjacent to F100, though the exact epitope region may differ

  • Other MMP antibodies: May target pro-domains, catalytic domains, or hemopexin domains without specific focus on activation-related cleavage sites

• Cross-reactivity profiles:

  • Cleaved-MMP1 (F100) Antibody has been validated for human samples, with some versions also reactive to rat and mouse samples

  • MMP family members share structural similarities, particularly in the catalytic domain, which may lead to cross-reactivity if antibodies are not carefully selected and validated

  • Sequence analysis and homology comparisons between MMPs can help predict potential cross-reactivity issues

• Applications versatility:

  • Both Cleaved-MMP1 (F100) and Cleaved-MMP3 (F100) Antibodies have been validated for Western Blot and ELISA applications

  • Cell-based assays have been developed for Cleaved-MMP1 (F100) detection, allowing for quantitative analysis in cellular contexts

  • Application-specific optimization may differ between MMP antibodies based on epitope accessibility and antibody characteristics

• Biological context differences:

  • MMP1: Primary role in degrading fibrillar collagens (types I, II, III)

  • MMP3: Broader substrate specificity, degrading "fibronectin, laminin, gelatins of type I, III, IV, and V collagens III, IV, X, and IX, and cartilage proteoglycans"

  • Understanding these functional differences is crucial when selecting appropriate antibodies for studying specific biological processes

What are the physiological and pathological roles of MMP1 that can be studied using this antibody?

The Cleaved-MMP1 (F100) Antibody can be utilized to investigate numerous physiological and pathological processes involving MMP1:

• Physiological roles:

  • Extracellular matrix remodeling during normal development and tissue homeostasis

  • Wound healing processes requiring collagen degradation and reorganization

  • Angiogenesis and vascular remodeling

  • Immune response modulation, as MMP1 "plays a role in immune response and possesses antiviral activity against various viruses such as vesicular stomatitis virus, influenza A virus (H1N1) and human herpes virus 1"

• Pathological processes:

  • Cancer progression and metastasis: MMP1 is often upregulated in various cancers

  • Lung tumorigenesis: Studies with Mmp1a-deficient mice showed "a greater than 50% reduction in the number of total tumor foci, with significantly fewer large lesions"

  • Inflammatory disorders: MMP1 may regulate "the balance between Th1/Th2 inflammatory responses"

  • Fibrotic diseases: MMP1 is "essential for normal collagen turnover, recovery from fibrosis, and vascular permeability"

  • Neurodegeneration: In dopaminergic neurons, MMP1 "gets activated by the serine protease HTRA2 upon stress and plays a pivotal role in DA neuronal degeneration"

• Receptor activation studies:

  • Protease-activated receptor-1 (PAR1) signaling: "MMP1 appears to be a pathophysiologic PAR1 agonist" in various disease models

  • Activation of PAR1 by MMP1 "occurs at a slightly different site from the canonical thrombin cleavage site, generating a slightly different ligand"

  • This unique signaling pathway can be studied using the antibody to correlate MMP1 activation with PAR1 signaling events

• Intracellular functions:

  • Nuclear translocation: MMP1 "translocates from the cytoplasm into the cell nucleus upon virus infection to influence NF-kappa-B activities"

  • Studying these non-canonical roles of MMP1 provides insight into broader functions beyond extracellular matrix degradation

What are the latest research developments involving cleaved MMP1 detection in various disease models?

Recent research developments involving cleaved MMP1 detection in disease models highlight several emerging areas:

• Cancer research applications:

  • Lung cancer models: Studies examining MMP1 activation in urethane-induced lung tumorigenesis revealed that "Mmp1a-deficiency protected mice from lung tumorigenesis," with significant reductions in tumor foci

  • Metastasis mechanisms: Investigation of MMP1's role in cancer cell invasion through collagen barriers, facilitating metastatic spread

  • Therapeutic targeting: Development of selective inhibitors that target active MMP1 while sparing other MMPs to reduce off-target effects

• Inflammatory disease investigations:

  • Immune modulation: Research showing that Mmp1a may be "involved in regulating the balance between Th1/Th2 inflammatory responses," with "Mmp1a −/− lungs [having] an increase in inflammatory infiltrate" and elevated levels of "Th1-associated cytokines, IL-1α, IL-2, IL-27, and IFN-γ"

  • Arthritis models: Studies of MMP1 activation in synovial tissues and its contribution to cartilage degradation

  • Inflammatory biomarkers: Exploration of cleaved MMP1 as a potential biomarker for inflammatory disease activity and progression

• Neurological disorder models:

  • Neurodegeneration: Investigation of MMP1's role in "DA neuronal degeneration by mediating microglial activation and alpha-synuclein/SNCA cleavage"

  • Blood-brain barrier studies: Examination of MMP1's contribution to blood-brain barrier integrity and neuroinflammation

  • Neurodevelopmental processes: Studies of MMP1 in axonal guidance and synovial plasticity

• Cardiovascular disease research:

  • Atherosclerosis: Studies of MMP1 activation in plaque stability and rupture

  • Cardiac remodeling: Investigation of MMP1's role in post-infarction remodeling

  • Vascular permeability: Research on MMP1's contribution to vascular integrity and edema formation

• Novel detection methodologies:

  • Electrogenerated chemiluminescence biosensors: Development of "ECL biosensor for quantization" of MMPs, where "When reacting with MMP-3, the ECL probe can be cleaved and part of the ECL probe can leave from the electrode surface; then the ECL intensity is decreased" - similar approaches could be adapted for MMP1

  • Single-molecule tracking: Advanced techniques to visualize MMP1 activity in real-time on native substrates

  • Computational modeling: Integration of "all-atom simulations" to predict MMP1 behavior in various disease contexts

What are the detailed storage and handling recommendations for Cleaved-MMP1 (F100) Antibody?

For optimal performance and longevity of Cleaved-MMP1 (F100) Antibody, follow these storage and handling recommendations:

• Storage conditions:

  • Temperature: Store at -20°C for long-term storage (up to 1 year)

  • Short-term storage: May be maintained at 2-8°C for up to 2 weeks

  • Aliquoting: Upon first thaw, divide into small aliquots to prevent freeze-thaw cycles

  • Container: Store in light-protected tubes to prevent photodegradation

• Buffer composition and stability factors:

  • Typical formulation: "Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide"

  • The glycerol content helps prevent freezing damage

  • BSA acts as a carrier protein to stabilize the antibody

  • Sodium azide prevents microbial contamination

• Handling precautions:

  • Avoid repeated freeze-thaw cycles as they can lead to protein denaturation and loss of activity

  • Thaw at 4°C (refrigerator) or on ice rather than at room temperature

  • Briefly centrifuge vials after thawing to recover all liquid

  • Use sterile technique when handling to prevent contamination

• Working solution preparation:

  • Dilute in appropriate buffer immediately before use

  • For Western blot: Typically diluted in blocking buffer (e.g., 5% non-fat milk or BSA in TBST)

  • For ELISA: Diluted in the recommended diluent buffer from the kit or a standard diluent

  • Use primary antibody diluent for optimal results

• Quality control considerations:

  • Expiration date: Typically 12 months from date of receipt when properly stored

  • Appearance: Should remain clear without precipitation

  • Performance validation: Consider including positive controls with each experiment to verify antibody activity

What optimization steps can improve detection sensitivity in challenging samples?

To improve detection sensitivity with Cleaved-MMP1 (F100) Antibody in challenging samples:

• Sample preparation enhancements:

  • Enrichment techniques: Consider immunoprecipitation to concentrate cleaved MMP1 before detection

  • Protein extraction optimization: Test different lysis buffers to maximize extraction efficiency while preserving epitope integrity

  • Reduction of interfering substances: Add appropriate blocking agents to minimize matrix interference

• Signal amplification strategies:

  • Enhanced detection systems: Use high-sensitivity ECL reagents for Western blot

  • Tyramide signal amplification: Provides significant signal enhancement for low-abundance targets

  • Polymer-based detection: HRP-polymer conjugated secondary antibodies can provide stronger signals than traditional secondaries

• Protocol modifications:

  • Extended primary antibody incubation: Overnight at 4°C can improve binding in low-abundance samples

  • Optimized antibody concentration: Titrate to determine optimal concentration for your specific sample type

  • Reduced washing stringency: Consider shorter or gentler washing steps to preserve weak signals

• Background reduction approaches:

  • Blocking optimization: Test different blocking agents (BSA, non-fat milk, commercial blockers)

  • Diluent additives: Include Tween-20 or other detergents to reduce non-specific binding

  • Secondary antibody selection: Choose highly cross-adsorbed secondary antibodies to minimize cross-reactivity

• Detection method selection:

  • For Western blot: Consider chemiluminescent, fluorescent, or chromogenic detection based on required sensitivity

  • For ELISA: Explore different substrate options (colorimetric, fluorescent, chemiluminescent) based on detection needs

  • For cell-based assays: Optimize cell fixation and permeabilization to maximize epitope accessibility

• Technical considerations for specific applications:

  • Western blot: Use PVDF membranes for higher protein binding capacity

  • ELISA: Consider sandwich ELISA format with capture antibody for improved specificity

  • Cell-based assays: Optimize cell density and treatment conditions